Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized Placebo-Controlled Trial of Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06081348
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:35.580589+00:00
Published At
2025-07-16T00:00:00+00:00
Record Updated At
2025-07-16
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Neurodevelopmental Disorders", "Autism", "Autism Spectrum Disorder", "Fragile X Syndrome", "Tuberous Sclerosis", "22Q11 Deletion Syndrome", "22Q11 Deletion", "ADHD", "Tic Disorders", "Tourette Syndrome", "Tourette Syndrome in Children", "Tourette Syndrome in Adolescence", "ADHD - Combined Type", "ADHD Predominantly Inattentive Type", "ADHD, Predominantly Hyperactive - Impulsive", "Anxiety", "Anxiety Disorders"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-07-16"
protocolSection.identificationModule.nctId
"NCT06081348"
protocolSection.identificationModule.officialTitle
"A Randomized Placebo-Controlled Trial of Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Neurodevelopmental Disorders (protocolSection.conditionsModule.conditions)
  • Autism (protocolSection.conditionsModule.conditions)
  • Autism Spectrum Disorder (protocolSection.conditionsModule.conditions)
  • Fragile X Syndrome (protocolSection.conditionsModule.conditions)
  • Tuberous Sclerosis (protocolSection.conditionsModule.conditions)
  • 22Q11 Deletion Syndrome (protocolSection.conditionsModule.conditions)
  • 22Q11 Deletion (protocolSection.conditionsModule.conditions)
  • ADHD (protocolSection.conditionsModule.conditions)
  • Tic Disorders (protocolSection.conditionsModule.conditions)
  • Tourette Syndrome (protocolSection.conditionsModule.conditions)
  • Tourette Syndrome in Children (protocolSection.conditionsModule.conditions)
  • Tourette Syndrome in Adolescence (protocolSection.conditionsModule.conditions)
  • ADHD - Combined Type (protocolSection.conditionsModule.conditions)
  • ADHD Predominantly Inattentive Type (protocolSection.conditionsModule.conditions)
  • ADHD, Predominantly Hyperactive - Impulsive (protocolSection.conditionsModule.conditions)
  • Anxiety (protocolSection.conditionsModule.conditions)
  • Anxiety Disorders (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.